Organization · Venture Capital
Axil Capital Partners, Axil Capital Advisors K.K.
Axil Capital is a Tokyo-based venture capital firm specializing in biomedical and healthcare technology investments. Founded in 2017, it focuses on early to late-stage ventures in the life sciences sector.
Overview
What Axil Capital Partners, Axil Capital Advisors K.K. does
What Axil Capital Partners, Axil Capital Advisors K.K. is
Axil Capital is a Tokyo-based venture capital firm specializing in biomedical and healthcare technology investments. Founded in 2017, it focuses on early to late-stage ventures in the life sciences sector.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2017
- Approximate age
- About 9 years
- Structured capabilities
- Funder
- Last reviewed
- April 29, 2026
Official channels
Find Axil Capital Partners, Axil Capital Advisors K.K. elsewhere
Open the official website or a supported primary organization account.
Capability profile
Axil Capital Partners, Axil Capital Advisors K.K. as a funder
Investment thesis
Axil Capital identifies, evaluates, executes, and nurtures investments across the full life-science spectrum, diversifying across early venture and late-stage crossover rounds. The firm emphasizes transformational technologies and services that can have long-term impact for the medical community while producing returns for investors.
Focus narrative
Axil Capital focuses on investments in the life sciences sector, covering a wide range of areas including biopharmaceuticals, platform technologies, medical devices, digital health, and healthcare services. The firm invests in early-stage ventures as well as late-stage crossover rounds, aiming to diversify its portfolio across various stages of development.
Value beyond capital
Axil Capital provides portfolio companies with capital, operational guidance, industry relationships, and access to growth resources, helping them build commercially viable enterprises.
Focus and fit
- Stages
- Seed · Friends and Family · Angel · Accelerator · Pre-seed · Series A · Series B · Series C · Growth Equity · Pre-IPO
- Sectors
- Biotech · Healthcare · Digital Health · Medical Devices
- Regions
- Asia · Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded notable exits
- Elixiron Immunotherapeutics
Portfolio context
Notable portfolio companies include: Elixiron Immunotherapeutics: Recently listed on the Taipei Emerging Market. LinqMed: Engaged in the development of radiopharmaceutical manufacturing. MabGenesis: Involved in the development of monoclonal antibody therapeutics for animals. CynosBio: Focused on clinical trials for osteoarthritis treatments. GEXVal: Participating in research programs for Parkinson's disease treatments.
Common questions
What to know about Axil Capital Partners, Axil Capital Advisors K.K.
Upseed classifies Axil Capital Partners, Axil Capital Advisors K.K. under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 29, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.